Methods for treatment of type 1 diabetes

• US 7,951,776 B2
• Filed: 07/01/2009
• Issued: 05/31/2011
• Est. Priority Date: 09/01/2006
• Status: Expired due to Fees

• Current Assignee: American Type Culture Collection
• Original Assignee: American Type Culture Collection
• Inventors: Gelber, Cohava
• Primary Examiner(s): Li; Ruixiang
• Application Number:
  US12/496,180
• Publication Number:
  US 20100184658A1
• Time in Patent Office: 699 Days
• Field of Search: None
• US Class Current: 514/7.3
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Claims

1. A method for treating Type 1 diabetes in a subject, the method comprising administering to a subject a therapeutically effective amount of the peptide of SEQ ID NO:

1.

2. The method of claim 1, further comprising the step of selecting a subject having Type 1 diabetes.

3. The method of claim 1, wherein the treatment results in an increased pancreatic beta cell mass in the subject.

4. The method of claim 1, wherein the subject is a mammal.

5. The method of claim 4, wherein the mammal is a human.

6. The method of claim 4, wherein the mammal is a domesticated animal.

7. The method of claim 1, wherein the peptide is administered by intraperitoneal or subcutaneous injection.

8. The method of claim 1, further comprising the step of measuring the level of adiponectin in the subject after treatment, wherein an increase in the level of adiponectin indicates the treatment is effective.

9. The method of claim 1, further comprising the step of measuring the level of interleukin-6 in the subject after treatment, wherein a decrease in the level of interleukin-6 indicates the treatment is effective.

10. The method of claim 1, wherein the fasting blood glucose level of the subject is reduced compared to the fasting blood glucose level of the subject prior to onset of treatment with the peptide.

11. The method of claim 1, wherein the level of HBA1c of the subject is reduced compared to the HBA1c level of the subject prior to onset of treatment with the peptide.

12. The method of claim 1, wherein the level of ketone bodies in the subject is reduced compared to the level of ketone bodies prior to onset of treatment with the peptide.

13. A method for delaying the onset of Type 1 diabetes in a subject, the method comprising administering to a subject a therapeutically effective amount of the peptide of SEQ ID NO:

1.

14. The method of claim 13, further comprising the step of selecting a subject at risk for developing Type 1 diabetes.

15. The method of claim 13, wherein the treatment results in an increased pancreatic beta cell mass in the subject.

16. The method of claim 13, wherein the subject is a mammal.

17. The method of claim 16, wherein the mammal is a human.

18. The method of claim 16, wherein the mammal is a domesticated animal.

19. The method of claim 13, wherein the peptide is administered by intraperitoneal or subcutaneous injection.